Jeffrey S. Heier

Active 1993–2025

Also published as
Jeffrey S Heier
100
Papers
30,818
Citations
68
h-index
98
i10-index

Citations

Citations per year for Jeffrey S. Heier1952: 1 citations1965: 5 citations1972: 1 citations1993: 1 citations1996: 2 citations1997: 2 citations1998: 1 citations1999: 2 citations2000: 5 citations2001: 1 citations2002: 3 citations2003: 3 citations2004: 2 citations2005: 11 citations2006: 52 citations2007: 164 citations2008: 187 citations2009: 154 citations2010: 186 citations2011: 209 citations2012: 252 citations2013: 292 citations2014: 298 citations2015: 275 citations2016: 231 citations2017: 220 citations2018: 160 citations2019: 742 citations2020: 778 citations2021: 783 citations2022: 563 citations2023: 575 citations2024: 1,197 citations2025: 589 citations2026: 6 citations1953–1964: no citations, so these years are not shown1966–1971: no citations, so these years are not shown1973–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,833 citing papers, 27.2% of this breakdownUnited Kingdom: 584 citing papers, 8.7% of this breakdownGermany: 383 citing papers, 5.7% of this breakdownChina: 370 citing papers, 5.5% of this breakdownSwitzerland: 306 citing papers, 4.5% of this breakdownJapan: 305 citing papers, 4.5% of this breakdownAustralia: 301 citing papers, 4.5% of this breakdownItaly: 301 citing papers, 4.5% of this breakdownFrance: 229 citing papers, 3.4% of this breakdownSingapore: 165 citing papers, 2.4% of this breakdownSpain: 147 citing papers, 2.2% of this breakdownCanada: 146 citing papers, 2.2% of this breakdown
0%27.2%Other 24.7%

Fields

  • Medicine83.8%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology1.3%
  • Neuroscience0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.7%
  • Other1.2%

Topics

  • Retinal Diseases and Treatments26.3%
  • Retinal Imaging and Analysis10%
  • Ocular Diseases and Behçet’s Syndrome7.9%
  • Ophthalmology and Visual Impairment Studies6.8%
  • Retinal and Optic Conditions5.1%
  • Retinal Development and Disorders4.9%
  • Other39%

Coauthors

All papers

Open in search
  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luis Arias, Jennifer Arnold, Riaz Asaria, Sergei Astakhov, Yury Astakhov, Carl C. Awh, Chandra Balaratnasingam, Sanjiv Banerjee, Caroline Baumal, Matthias Becker, Rubens Belfort, Galina Bratko, William Jr. Z Bridges, Jamin Brown, David M. Brown, Maria Budzinskaya, Sylvia Buffet, Stuart Burgess, Iksoo Byon, Carlo Cagini, Jorge Calzada, Stone Cameron, Peter Campochiaro, John Carlson, Angela Carneiro, Clement Chan, Emmanuel Chang, Andrew Chang, Daniel Chao, Nauman Chaudhry, Caroline Chee, Andrew Cheek, Shih-Jen Chen, San-Ni Chen, Gemmy Cheung, Saradha Chexal, Mark Chittum, David Chow, Abosede Cole, Brian Connolly, Pierre Loic Cornut, Stephen Couvillion, Carl Danzig, Vesselin Daskalov, Amr Dessouki, Francois Devin, Michael Dollin, Rosa Dolz, Louise Downey, Richard Dreyer, Pravin Dugel, David Eichenbaum, Bora Eldem, Robert Engstrom, Joan Josep Escobar, Nicole Eter, David W. Faber, Naomi Falk, Leonard Feiner, Alvaro Fernandez Vega, Philip Ferrone, Marta Figueroa, Howard Fine, Mitchell Fineman, Gregory M. Fox, Catherine Francais, Pablo Franco, Samantha Fraser-Bell, Nicholas Fung, Federico Furno Sola and 218 more - The Lancet 2022 cited by 686

  2. Ranibizumab for Neovascular Age-Related Macular Degeneration

    Authors: , , , , , , - New England Journal of Medicine 2006 cited by 5,866

  3. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander M. Eaton, Alexander Rubowitz, Alice T. Lyon, Allen Chiang, Allen C. Ho, Allen Hu, Amir Guerami, Amr Dessouki, André Corrêa Maia de Carvalho, Andrés Emanuelli, Andrew Chang, Andrew N. Antoszyk, A Francone, Anita Prasad, Armin Wolf, Arshad M. Khanani, Ashkan M. Abbey, Asma Moulana, Barbara Wihelm, Bartosz L. Sikorski, Baruch D. Kuppermann, Benjamin Wolff, Brian Jewart, K. Brian, Brian T. Chan-Kai, Calvin E. Mein, Carel B. Hoyng, Carl C. Awh, Carl Regillio, Carlos Zeolite, Caroline R. Baumal, Catherine Creuzot‐Garcher, Catherine Français Maury, Charles C. Wykoff, Charles K Newell, Chirag Jhaveri, Chris P. Lohmann, Christiana Dinah, Colin Ma, Courtney Crawford, D Wilkin Parke, Daniel Lavinsky, Daniel B. Roth, Dante J. Pieramici, Darius M. Moshfeghi, Darrin Levin, David A. Saperstein, David M. Brown, David Gaucher, David R. Lally, David Liao, David Warren Brown, Debra A. Goldstein, Dennis M. Marcus, Derek G. Chan, Dilsher S. Dhoot, Domingo Tacite, Dominik Zalewski, Edgar M. Espana, Eleonora M. Lad, Eric H. Souied, Eric Suan, Eva Eting, Federico Furno Sola, F. De Bats, Francesco Bandello, Francisco Gómez‐Ulla, François Devin, Frank G. Holz, Fred K. Chen and 163 more - The Lancet 2023 cited by 443

  4. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

    Authors: , , , , , , , , , , , , , , , , , , , - Ophthalmology 2012 cited by 2,470

  5. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisa E. Cornish, Thanh N. Nguyen, Oliver Findl, Anton Haas, Martina Kralinger, Stefan Sacu, Laurence Postelmans, Michel Eid Farah, Maurício Maia, Márcio Bittar Nehemy, Fareed Ali, Michael H. Brent, Michael Dollin, John R. Gonder, Amin Kherani, Andrew Merkur, Raman Tuli, Monica Marie Lopera, Francisco J. Rodríguez, Mario Bradvica, Jan Ernest, Kuldar Kalijurand, Kai Noor, Yves Cohen, Catherine Creuzot‐Garcher, F. De Bats, François Devin, Catherine Français-Maury, Laurent Kodjikian, Jean François Korobelnik, Y. Le Mer, M. Quaranta El Maftouhi, Sam Razavi, Eric H. Souied, Ramin Tadayoni, Michel Weber, Nicole Eter, Nicolas Feltgen, Salvatore Grisanti, Peter Walter, Raffael Liegl, Katrin Lorenz, Georg Spital, Siegfried Priglinger, Martin S. Spitzer, Michael Völker, Tim U. Krohne, Claudia Jochmann, Chris P. Lohmann, Carsten Framme, Ágnes Kerényi, András Papp, András Seres, Edit Tóth‐Molnár, Alexis Tsorbatzoglou, A VAJAS, Balázs Varsányi, Gábor Vogt, Asaf Bar, Eva Eting, David Hauser, Jamie Levy, Nurit Mathalone, Haia Morori-Katz, Irit Rosenblatt, Shiri Soudry-Zayit, Omert Trivizky, Francesco Bandello, Antonio P. Ciardella, Michele Figus and 126 more - The Lancet 2023 cited by 315

  6. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

    Authors: , , , , , , , , , , , , , , , , , , , , - Ophthalmology 2019 cited by 512

  7. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

    Authors: , , , , , , , - New England Journal of Medicine 2006 cited by 3,503

  8. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2024 cited by 219

  9. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

    Authors: , , , , , , , , , , - Eye 2023 cited by 130

  10. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

    Authors: , , , , , , , , , , , - Ophthalmology 2020 cited by 349

  11. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Edwards, Carl W. Baker, Michael Novák, Ricky D. Isernhagen, Todd E. Schneiderman, Lawrence S. Halperin, Michael H. Lee, David S. Boyer, Philip J. Rosenfeld, Pamela Rath, Marc H. Levy, Robert H. Rosa, John C. Hoskins, Clement K. Chan, David M. Brown, Craig M. Greven, J Michael Jumper, Linda J. Margulies, William N. Rosenthal, Richard B. Rosen, Glenn Stoller, Fadi El Baba, W. Copley McLean, Ronald Kingsley, Alice T. Lyon, Jeffrey S. Heier, Anne E. Fung, Ingrid U. Scott, John A. Wells, Michael J. Banach, Paul M. Beer, James C. Folk, Joseph I. Maguire, Srinivas R. Sadda, Richard A. Garfinkel, Judy E. Kim, Paul Berstein, Michael Rauser, Richard A. Lewis, Barron C. Fishburne, Suber Huang, Nelson R. Sabates, Nicola Kim, Robert N. Frank, Brian C. Joondeph, Odette M. Houghton, Dean P. Hainsworth, Edward Chaum, Robert H. Millay, Raymond Iezzi, Rajendra S. Apte, Ron A. Adelman, Anita Agrawal, Neelakshi Bhagat, Lawrence Ulanski, Steven D. Schwartz, Cynthia Owsley, Alan Letson, Yu-Guang He, Cynthia A. Toth, Lawrence S. Morse, Michael J. Cooney, Sandeep Grover, Henry Ferreyra, Alexander J. Brucker, David DiLoreto, Aaron Weinberg - JAMA Ophthalmology 2022 cited by 172

  12. Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

    Authors: , , , , , , , - Ophthalmology 2013 cited by 502

  13. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

    Authors: , , , , , - Ophthalmology 2008 cited by 1,316

  14. TENAYA and LUCERNE

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew N. Antoszyk, Etelka Aradi, Luís Arias, Jennifer Arnold, Riaz Asaria, Sergei Astakhov, Yury S. Astakhov, Carl C. Awh, Chandra Balaratnasingam, Sanjiv Banerjee, Caroline R. Baumal, Matthias Becker, Rubens Belfort, Galina Bratko, William Bridges, Jamin S. Brown, David M. Brown, M V Budzinskaya, S. Buffet, Stuart C Burgess, Ik Soo Byon, Carlo Cagini, Jorge I. Calzada, Stone Cameron, Peter A. Campochiaro, John S. Carlson, Ângela Carneiro, Clement Chan, Emmanuel Chang, Andrew Chang, Daniel L. Chao, Nauman Chaudhry, Caroline Chee, Andrew Cheek, Shih‐Jen Chen, San‐Ni Chen, Gemmy Cheung, Saradha Chexal, Mark Chittum, David R. Chow, Abosede Cole, B. Connolly, Pierre Loïc Cornut, Stephen Couvillion, Carl J. Danzig, Vesselin Daskalov, Amr Dessouki, François Devin, Michael Dollin, Rosa Dolz, Louise Downey, Richard F. Dreyer, Pravin U. Dugel, David Eichenbaum, Bora Eldem, Robert E. Engstrom, Joan Josep Escobar, Nicole Eter, David Faber, Naomi S. Falk, Leonard Feiner, Alvaro Fernandez Vega, Philip J. Ferrone, Marta S. Figueroa, Howard F. Fine, Mitchell S. Fineman, Gregory M. Fox, Catherine Français, Pablo Moreno Franco, Samantha Fraser‐Bell and 217 more - Ophthalmology 2024 cited by 179

  15. Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

    Authors: , , , , , , , , , , , , , , , , , , , , , - Ophthalmology 2013 cited by 811

  16. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

    Authors: , , , , , , , , , , , - The Lancet 2024 cited by 119

  17. TENAYA and LUCERNE

    Authors: , , , , , , , , , , , , - Ophthalmology Science 2021 cited by 84

  18. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

    Authors: , , , , , , , , , , , , , , , - The Lancet 2017 cited by 226

  19. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fareed Ali, Payam Amini, Andres Emanuelli Anzalotta, György Bátor, Ivan R. Batlle, Adam Berger, Ramanath Bhandari, William Bridges, Christian Brinkmann, Jamin S. Brown, Stuart C Burgess, Jorge I. Calzada, Antonio Capone, Dana Cervena, Steven Charles, Nauman Chaudhry, David R. Chow, W. Lloyd Clark, Paul Conrad, Matthew A. Cunningham, Hajir Dadgostar, Amr Dessouki, Dana Madison Deupree, Christopher A. Devine, David Eichenbaum, Jan Ernest, Nicolas Feltgen, M. J. Fenberg, Philip J. Ferrone, R. E. P. Frenkel, Scott M. Friedman, Julie Gasperini, Adam T. Gerstenblith, Ghassan Ghorayeb, Michel Giunta, Mitchell J. Goff, Liliya Golas, Joseph M. Googe, Jordana Fein, Curtis Hagedorn, Akira Hagiwara, Paul Hahn, Richard Hairston, Jason M. Handza, Vivienne Hau, Ken Hayashi, Jeffrey S. Heier, Vrinda Hershberger, Patrick Higgins, Yoshio Hirano, Shigeru Honda, Yasuko Ikegami, Yuichiro Ishida, Isao Ishikawa, Kiyoshi Ishii, Eric Jablon, Atul Jain, Yuichi Kaji, Kapil Kapoor, Ágnes Kerényi, Kazuhiro Kimura, Genichiro Kishino, Katalin Kiss, Takashi Kitaoka, James M. Klancnik, Namie Kobayashi, Jiro Kogo, Vladimír Korda, Erik Kruger, Sentaro Kusuhara and 55 more - The Lancet 2024 cited by 113

  20. THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES

    Authors: , , , , , , , , , - Retina 2020 cited by 110

  21. Visual Function Decline Resulting from Geographic Atrophy

    Authors: , , , , , , , , , , , , , - Ophthalmology Retina 2020 cited by 106

  22. Intravitreal Aflibercept for Diabetic Macular Edema

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Ophthalmology 2014 cited by 807

  23. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy

    Authors: , , , , , , , , , , , , , , - JAMA Ophthalmology 2021 cited by 148

  24. Intravitreal Aflibercept for Diabetic Macular Edema

    Authors: , , , , , , , , , , , , , , , , , , , , - Ophthalmology 2016 cited by 421